Letermovir for the compassionate therapeutic use of cytomegalovirus infection
Tóm tắt
Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
Tài liệu tham khảo
Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L et al (2018) The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900–931. https://doi.org/10.1097/TP.0000000000002191
Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689–712. https://doi.org/10.1128/CMR.00009-10
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433–2444. https://doi.org/10.1056/NEJMoa1706640
Ligat G, Cazal R, Hantz S, Alain S (2018) The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev 42:137–145. https://doi.org/10.1093/femsre/fuy004
Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P et al (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:1079–1084. https://doi.org/10.1111/j.1600-6143.2011.03530.x
Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW et al (2019) Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02337-18
Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D et al (2020) Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. https://doi.org/10.1097/TP.0000000000002785
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G et al (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. https://doi.org/10.1093/cid/ciw668
Humar A, Kumar D, Boivin G, Caliendo AM (2002) Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186:829–833. https://doi.org/10.1086/342601
Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S (2018) Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 18:3060–3064. https://doi.org/10.1111/ajt.15135
Lischka P, Michel D, Zimmermann H (2016) Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 213:23–30. https://doi.org/10.1093/infdis/jiv352
Jung S, Michel M, Stamminger T, Michel D (2019) Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis 19. https://doi.org/10.1186/s12879-019-4016-1
Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M et al (2020) Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis. https://doi.org/10.1093/infdis/jiz577
Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M et al (2014) Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 27:77–86. https://doi.org/10.1111/tri.12225